An influence of therapy agaist renal anemia and secondary hyperparathyroidism on iron dysregulation in patients with chronic kidney disease
Not Applicable
Recruiting
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000011613
- Lead Sponsor
- Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Malignant disease, hematological disease, severe infection, bleeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A decrease in serum level of ferritin
- Secondary Outcome Measures
Name Time Method Anemia/iron: ESA responsiveness, serum iron, TIBC, Tsat, hepcidin, frataxin, sTfR, etc. Oxidative stress/inflammation: 8OHdG, AOPP, MDA, GSH, PNT, high-sensitivity CRP,TNF, IL-6, etc. MBD: iPTH, wPTH, BAP, TRAP5b, vitaminD,TropT, PTX, FGF23, etc